Show Summary Details
Page of

(p. 187) Combining Exposure Therapy with Medications 

(p. 187) Combining Exposure Therapy with Medications
(p. 187) Combining Exposure Therapy with Medications

Jasper A. J. Smits

, Mark B. Powers

, and Michael W. Otto

Page of

PRINTED FROM OXFORD CLINICAL PSYCHOLOGY ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Clinical Psychology Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 August 2020

Chapter 8 covers the impact of combined medication and exposure treatments. Any time two treatments coincide, there is a risk that patients may wonder what gains are associated with which treatment. Fortunately, the research supports that patients who are taking medications still benefit from exposure therapy. However, if medication is discontinued after therapy, there is a risk of relapse due to misattribution and withdrawal symptoms. This is particularly true for benzodiazepine medications. Ideally, patients will agree to either eliminate use of benzodiazepines before exposure begins or at least switch from an as needed basis to scheduled dosing regimen. If, however, the patient completes exposure in the context of a medication he or she intends to discontinue, the authors recommend several strategies to protect against relapse. Interoceptive exposure can be helpful in preparing for a medication taper by learning safety even during uncomfortable withdrawal sensations. In addition, the authors recommend a slow taper combined with exposure before, during, and after medication discontinuation.

Access to the complete content on Oxford Clinical Psychology requires a subscription or purchase. Public users are able to search the site and view the abstracts and keywords for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.